Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Eton Pharmaceuticals (NASDAQ:ETON) Raised to Hold at Zacks Investment Research

researchsnappy by researchsnappy
December 24, 2019
in Healthcare Research
0
SalMar ASA (OTCMKTS:SALRF) Rating Increased to Hold at Nordea Equity Research
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Eton Pharmaceuticals logoEton Pharmaceuticals (NASDAQ:ETON) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday, Zacks.com reports.

According to Zacks, “Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois. “

ETON has been the subject of a number of other research reports. B. Riley initiated coverage on shares of Eton Pharmaceuticals in a research report on Friday, September 20th. They set a “buy” rating and a $13.50 target price for the company. HC Wainwright restated a “buy” rating and set a $21.00 price target (up previously from $18.00) on shares of Eton Pharmaceuticals in a report on Wednesday, October 23rd. Finally, ValuEngine downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $13.75.

Shares of NASDAQ ETON traded up $0.08 during trading on Monday, reaching $6.98. The company had a trading volume of 83,900 shares, compared to its average volume of 68,994. The stock has a market cap of $122.87 million and a P/E ratio of -1.20. The company’s fifty day moving average price is $6.16 and its 200-day moving average price is $6.44. Eton Pharmaceuticals has a 12 month low of $5.13 and a 12 month high of $10.20.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Thursday, November 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05). As a group, sell-side analysts forecast that Eton Pharmaceuticals will post -1.13 EPS for the current year.

A number of institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC grew its holdings in Eton Pharmaceuticals by 122.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,139 shares of the company’s stock worth $25,000 after acquiring an additional 1,728 shares during the period. Vanguard Group Inc. lifted its stake in shares of Eton Pharmaceuticals by 6.7% in the 2nd quarter. Vanguard Group Inc. now owns 28,762 shares of the company’s stock valued at $227,000 after purchasing an additional 1,800 shares during the period. BlackRock Inc. boosted its position in shares of Eton Pharmaceuticals by 181.2% during the 2nd quarter. BlackRock Inc. now owns 26,092 shares of the company’s stock valued at $206,000 after purchasing an additional 16,813 shares in the last quarter. First Trust Advisors LP bought a new stake in shares of Eton Pharmaceuticals during the 3rd quarter valued at about $155,000. Finally, First Allied Advisory Services Inc. acquired a new stake in Eton Pharmaceuticals during the third quarter worth approximately $228,000. Hedge funds and other institutional investors own 12.80% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.

See Also: What is the Coverage Ratio?

Get a free copy of the Zacks research report on Eton Pharmaceuticals (ETON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com



Receive News & Ratings for Eton Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eton Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

Relation of the Psychological Constructs of Resilience, Mindfulness, a

Next Post

Increase per-pupil funding to improve Michigan education

Next Post
Increase per-pupil funding to improve Michigan education

Increase per-pupil funding to improve Michigan education

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

Pa. Republicans reconsider Pitt funding over fetal tissue research, college voucher program

Arthur Pharma Closes Series A Financing Round

YouTube and the Achilles Tendon: An Analysis of Internet Information Reliability and Content Quality

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2022 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2022 researchsnappy.com